Improved T Cell Expansion Using Closed, Automated Stirred-Tank Bioreactors And CTS OpTmizer Pro SFM

The T cell therapy market is projected to reach $20.3 billion by 2028, and the success of these therapies hinges on effective, scalable T cell expansion. While rocking motion bioreactors have been a staple, stirred-tank bioreactors are gaining traction due to their potential advantages in scalability, smaller footprint, and enhanced control over the cell environment.

This application note explores how closed, automated stirred-tank bioreactors, when used with CTS™ OpTmizer™ Pro SFM, can lead to improved T cell expansion. The study compares the performance of stirred-tank bioreactors to rocking motion and static systems, evaluating key parameters like fold expansion, cell viability, and phenotype. It also investigates the impact of different agitation and feeding strategies to optimize T cell growth.

Access the full application note to gain insights into enhancing your T cell manufacturing.